These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 17086090

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M, Sada T, Kato M, Koike H.
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [Abstract] [Full Text] [Related]

  • 3. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T.
    Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
    [Abstract] [Full Text] [Related]

  • 11. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
    Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K.
    J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M.
    Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.
    Yamagishi S, Takeuchi M, Inoue H.
    Drugs Exp Clin Res; 2005 Oct; 31(2):45-51. PubMed ID: 15929605
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.